Amisulpride and risperidone are potent dopamine D2 receptor blocking atypical antipsychotics that can cause hyperprolactinemia. Preclinical evidence shows that chronic administration of antipsychotics can cause pituitary adenomas in female mice. To investigate the clinical relevance in this finding, reports of pituitary neoplasms in the WHO adverse drug reaction (ADR) database were reviewed. Amisulpride and risperidone [corrected] had among the highest Information Component (IC) scores for benign pituitary neoplasm; amisulpride (IC = 3.31, IC025 = 1.83, 5 reports) and risperidone (IC = 4.03, IC025 = 3.33, 19 reports), and not otherwise specified (NOS) pituitary neoplasm: amisulpride (IC = 2.69, IC025 = 0.70, 3 reports) and risperidone (IC = 4.49, IC025 = 3.86, 23 reports). We conclude that there is a need for prospective studies to confirm causality and suggest that clinicians, until then, would consider a pituitary adenoma in patients experiencing severe hyperprolactinemia or associated symptoms when receiving potent D2 antagonists [corrected]
Download full-text PDF |
Source |
---|
Neuropharmacology
December 2024
State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China; Neuroscience center, Chinese Academy of Medical Sciences, Beijing, China. Electronic address:
Objective: Autoantibody-associated psychosis represents a distinct disease subgroup of patients with schizophrenia with a suspected autoimmune origin. Although preliminary studies have suggested adjunctive drug treatment strategies targeting the immune system, further validation of these findings is warranted. Autoantibodies against SFT2D2 have been identified in patients with schizophrenia.
View Article and Find Full Text PDFBrain Res
December 2024
Ningxia Clinical Research Institute, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, PR China.
The study aimed to examine the effects of Quetiapine, an atypical antipsychotic medication with purported neuroprotective qualities, on cognitive function and synaptic plasticity in epileptic rats. This investigation also sought to elucidate the mechanisms by which quetiapine influences the activity of the cyclic adenylate response element binding protein (CREB)/brain-derived neurotrophic factor (BDNF) signaling pathway and metallomatrix proteinase-9 (MMP9) expression in the context of epilepsy. The epileptic model was induced in rats through the administration of pilocarpine, with normal rats serving as the control group.
View Article and Find Full Text PDFPediatr Rep
December 2024
Department of Pediatric Neurology, Queen Rania Children's Hospital, Royal Medical Services, Amman 11118, Jordan.
Background/objectives: Routine screening electrocardiograms (ECGs) prior to starting medications for attention-deficit/hyperactivity disorder (ADHD) remain controversial. This real-world study assessed corrected QT (QTc) interval data from pediatric patients who had a baseline ECG performed prior to initiating treatment with ADHD medications and ≥6 months of clinical follow-up.
Methods: A retrospective chart review of children aged 2-18 years diagnosed with ADHD with/without autism spectrum disorder (ASD) at child neurology clinics in Jordan (June 2019 and June 2021) was performed, and children were prescribed with ADHD medications to manage symptoms.
ACS Appl Bio Mater
December 2024
Polymers & Functional Materials Division, CSIR- Indian Institute of Chemical Technology, Hyderabad 500007, India.
Neurological disorders impact global health by affecting both central and peripheral nervous systems. Understanding the neurogenic processes, i.e.
View Article and Find Full Text PDFInt J Dev Disabil
March 2024
Child and Adolescent Psychiatry Department, Manisa Celal Bayar University Faculty of Medicine, Manisa, Turkey.
Objectives: Autistic children frequently exhibit irritability, which can manifest as aggression, self-injurious behaviour, and severe tantrums, leading to significant impairments. Two atypical antipsychotics have been licensed by the Food and Drug Administration for the treatment of irritability in autistic children, although a significant percentage of these children do not respond to this treatment. This study aimed to determine the frequency of drug refractory irritability (DRI) and identify the risk factors in a large clinical sample of autistic children.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!